Efficacy and Safety of Injection With VINCI Plus Hyaluronic Acid Filler

D.med

Status

Completed

Conditions

Nasolabial Fold Improvement

Treatments

Device: VINCI Plus

Device: Restylane-L

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01918839

DMEDVINCI001 (Other Identifier)

Details and patient eligibility

About

This clinical trial is intended to evaluate the efficacy and safety of injection with VINCI Plus as compared to Restylane-L® in correction of nasolabial fold.

Enrollment

46 patients

Sex

All

Ages

30 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female between the ages of 30-65, at the point of screening, wrinkles on both sides of treatment area (nasolabial fold) are in the 3rd or 4th level on the WSRS(Wrinkle Severity Rating Score)
Surrounding soft tissue of wrinkles on both sides of nose and lips are sagging
Wrinkles of both sides of nose and lips are visually symmetric
Agrees to stop all other treatment of facial wrinkle improvement including dermatology treatment during clinical trial
Able to understand and follow instructions and participate the entire period of the clinical trial
Subject voluntarily agrees to participate in clinical trial and gives informed written consent

Exclusion criteria

At the point of screening, intradermal test results show skin irritation to medical devices of clinical trial
Within 2 weeks before the date of screening, subject has taken antithrombotic (with the exception of low dose aspirin 100mg, up to 300mg/day) or non-steroidal anti-inflammatory medication
Case where subject has abnormal liver function or blood coagulation, has to take antithrombotic medication (with the exception of low dose aspirin 100mg, up to 300mg/day) during clinical trial
Subject has used facial topical liniment (steroids, retinoids: excluding only medicines and cosmetics) within 4 weeks before date of screening or plans to continue using facial topical liniment during clinical trial
Within 6 months before date of screening, subject has received anti-wrinkle or acne treatment
Within 6 months before date of screening, subject has received facial microdermabrasion treatment, skin regeneration/rejuvenation treatment, plastic surgery, or cosmetic surgery (including Botox injections)
Within 1 year before date of screening, subject has received CaHA (Calcium Hydroxyapatite) treatment on clinical trial medical device treatment area
Subject has cured facial gel (Softform) or silicone implants inserted as permanent facial expansion
Within 1 year before, subject had an illness that caused scarring or has scars on clinical trial medical device treatment area
Subject has facial skin disease or skin wound infection that affects the clinical trial
Weak immune system or suspect that the immune system is weak
History of anaphylaxis or severe allergic complexity
History of hypertrophic scar or keloid
In the past, if there were adverse effects from EMLA Cream (if EMLA Cream was not used, the exclusion criteria for subjects applicable)
History of hypersensitivity to Lidocaine
Cardiovascular, digestive, respiratory, endocrine, central nervous system disorders that seems clinically significant or had a mental illness that had a significant impact on a previous clinical trial or currently has a mental illness
Within 30 days before screening, subject participated in other clinical trials
Female subjects of childbearing potential does not agree to a medically accepted method of contraception for the period of the clinical trial Medically acceptable methods of contraception: condoms; oral contraception continued for at least three months; or if intrauterine is used, installed a contraceptive device
Pregnant women or nursing mothers
In addition to the above, the test director or person in charge medically judges there are clinically significant findings that are improper for the clinical trial